{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["55(4)"],"submitter":["Ryan AL"],"pubmed_abstract":["Influenza vaccination is recommended for children following allogeneic haematopoietic stem cell transplant (HSCT), however there is limited evidence regarding its benefit. A prospective multicentre study was conducted to evaluate the immunogenicity of the inactivated influenza vaccine in children who have undergone HSCT compared with healthy age-matched controls. Participants were vaccinated between 2013 and 2016 according to Australian guidelines. Influenza-specific hemagglutinin inhibition antibody titres were performed prior to each vaccination and 4 weeks following the final vaccination. A nasopharyngeal aspirate for influenza was performed on participants that developed influenza-like illness. There were 86 children recruited; 43 who had undergone HSCT and 43 controls. For the HSCT gr"],"journal":["Bone marrow transplantation"],"pagination":["773-779"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7223911"],"repository":["biostudies-literature"],"pubmed_title":["Immunogenicity of the inactivated influenza vaccine in children who have undergone allogeneic haematopoietic stem cell transplant."],"pmcid":["PMC7223911"],"pubmed_authors":["Kerr F","Richmond PC","Carolan LA","Barr IG","Wadia UD","Blyth CC","Jacoby P","Laurie KL","Fraser C","Mechinaud F","Cheung LC","Ryan AL","Tapp H","Kotecha RS","Gottardo NG"],"additional_accession":[]},"is_claimable":false,"name":"Immunogenicity of the inactivated influenza vaccine in children who have undergone allogeneic haematopoietic stem cell transplant.","description":"Influenza vaccination is recommended for children following allogeneic haematopoietic stem cell transplant (HSCT), however there is limited evidence regarding its benefit. A prospective multicentre study was conducted to evaluate the immunogenicity of the inactivated influenza vaccine in children who have undergone HSCT compared with healthy age-matched controls. Participants were vaccinated between 2013 and 2016 according to Australian guidelines. Influenza-specific hemagglutinin inhibition antibody titres were performed prior to each vaccination and 4 weeks following the final vaccination. A nasopharyngeal aspirate for influenza was performed on participants that developed influenza-like illness. There were 86 children recruited; 43 who had undergone HSCT and 43 controls. For the HSCT gr","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Apr","modification":"2025-04-19T01:47:15.332Z","creation":"2020-05-22T20:14:53Z"},"accession":"S-EPMC7223911","cross_references":{"pubmed":["31659236"],"doi":["10.1038/s41409-019-0728-5"]}}